Serum thyrotropin and thyroxine concentrations in patients recieving lithium carbonate.
Serum thyrotropin and thyroxine concentrations in patients recieving lithium carbonate.
复制标题
接受碳酸锂的患者的血清促甲状腺素和甲状腺素浓度。
DOI：
--
复制
发表时间：
1973
影响因子：
5.8
通讯作者：
R. Utiger
中科院分区：
文献类型：
--
作者：
Charles H. Emerson;William L. Dyson;R. Utiger
为了解碳酸锂治疗后甲状腺功能障碍的发生率，对255例接受碳酸锂治疗的患者进行了促甲状腺激素(TSH)和甲状腺素(T4)的动态测定。患者平均随访8个月，最长的锂治疗时间为65个月。锂治疗组患者的平均峰值促甲状腺激素水平是对照组的3倍；29.8%的患者(76)在治疗期间的某个时间出现(>；8μU/ml)促甲状腺激素水平升高。在最终测试时，14.1%(36)的患者血清TSH水平升高。锂治疗组患者的平均甲状腺激素峰值和终末浓度仅略低于对照组。15例血清TSH值>20μU/ml的患者，甲状腺激素平均浓度为2.9μg/100ml，抗甲状腺球蛋白抗体阳性率明显高于对照组。大多数人都考虑过..。
To determine the incidence of thyroid dysfunction in patients receiving therapy with lithium carbonate, serial determinations of serum thyrotropin (TSH) and thyroxine (T4) concentrations were made in 255 patients receiving lithium. The patients were followed for an average of 8 months and the longest period of lithium treatment was 65 months. The mean peak TSH level in the lithium treated patients was 3 times higher than in the control groups; elevated (>8 μU/ml) TSH levels occurred in 29.8% of the patients (76) at some time during treatment. At the time of final testing, 14.1% (36) of the patients had elevated serum TSH levels. The mean peak and final thyroxine concentrations in the lithium treated patients were only slightly lower than those in the control groups. In 15 patients whose final serum TSH levels were over 20 μU/ml, the mean thyroxine concentration was 2.9 μg/100 ml. A significantly higher incidence of positive anti-thyroglobulin antibody tests was found in these patients. Most were considere...